Literature DB >> 17197875

HIV and malaria: interactions and implications.

Laurence Slutsker1, Barbara J Marston.   

Abstract

PURPOSE OF REVIEW: This review summarizes accumulating evidence of interactions between HIV and malaria and implications related to prevention and treatment of coinfection. RECENT
FINDINGS: HIV-infected persons are at increased risk for clinical malaria; the risk is greatest when immune suppression is advanced. Adults with advanced HIV may be at risk for failure of malaria treatment, especially with sulfa-based therapies. Malaria is associated with increases in HIV viral load that, while modest, may impact HIV progression or the risk of HIV transmission. Cotrimoxazole prophylaxis greatly reduces the risk of malaria in people with HIV; the risk can be further reduced with antiretroviral treatment and the use of insecticide treated mosquito nets. Increased numbers of doses of intermittent preventive treatment during pregnancy can reduce the risk of placental malaria in women with HIV.
SUMMARY: Interactions between malaria and HIV have important public health implications. People with HIV should use cotrimoxazole and insecticide treated mosquito nets. Malaria prevention is particularly important for pregnant women with HIV, although more information is needed about the best combination of strategies for prevention. In people with HIV, malaria diagnoses should be confirmed, highly effective drugs should be used for treatment, and possible drug interactions should be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17197875     DOI: 10.1097/QCO.0b013e328012c5cd

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  20 in total

Review 1.  The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis.

Authors:  Ruanne V Barnabas; Emily L Webb; Helen A Weiss; Judith N Wasserheit
Journal:  AIDS       Date:  2011-08-24       Impact factor: 4.177

2.  Editorial commentary on: Malaria parasitaemia among long distance truck drivers in the Niger delta of Nigeria.

Authors:  A Mpimbaza; J Achan
Journal:  Afr Health Sci       Date:  2012-06       Impact factor: 0.927

3.  Virus infection stages and distinct Th1 or Th17/Th22 T-cell responses in malaria/SHIV coinfection correlate with different outcomes of disease.

Authors:  Bridgett Ryan-Payseur; Zahida Ali; Dan Huang; Crystal Y Chen; Lin Yan; Richard C Wang; William E Collins; Yunqi Wang; Zheng W Chen
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

4.  In vitro metabolism of piperaquine is primarily mediated by CYP3A4.

Authors:  Tina Ming-Na Lee; Liusheng Huang; Marla K Johnson; Patricia Lizak; Deanna Kroetz; Francesca Aweeka; Sunil Parikh
Journal:  Xenobiotica       Date:  2012-06-06       Impact factor: 1.908

Review 5.  Impact of cotrimoxazole and insecticide-treated nets for malaria prevention on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review.

Authors:  Ahmed Saadani Hassani; Barbara J Marston
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

6.  Using an improved phagocytosis assay to evaluate the effect of HIV on specific antibodies to pregnancy-associated malaria.

Authors:  Ricardo Ataíde; Wina Hasang; Danny W Wilson; James G Beeson; Victor Mwapasa; Malcolm E Molyneux; Steven R Meshnick; Stephen J Rogerson
Journal:  PLoS One       Date:  2010-05-25       Impact factor: 3.240

7.  Burden of asymptomatic malaria, anemia and relationship with cotrimoxazole use and CD4 cell count among HIV1-infected adults living in Gabon, Central Africa.

Authors:  Marielle Karine Bouyou Akotet; Jeanne Vanessa Koumba Lengongo; Magloire Ondounda; Eric Kendjo; Arnaud Mongo Delis; Magalie Essomeyo Mebale; Jacques Mari Ndong Ngomo; Noé Patrick M Bondoukwe; Denise Patricia Mawili-Mboumba; Madeleine Okome Nkoumou
Journal:  Pathog Glob Health       Date:  2017-11-21       Impact factor: 2.894

8.  Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.

Authors:  U Lek-Uthai; R Suwanarusk; R Ruengweerayut; T S Skinner-Adams; F Nosten; D L Gardiner; P Boonma; K A Piera; K T Andrews; B Machunter; J S McCarthy; N M Anstey; R N Price; B Russell
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

9.  HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.

Authors:  Charlotte V Hobbs; Tatiana Voza; Alida Coppi; Brian Kirmse; Kennan Marsh; William Borkowsky; Photini Sinnis
Journal:  J Infect Dis       Date:  2009-01-01       Impact factor: 5.226

10.  Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania.

Authors:  Theonest K Mutabingwa; Kandi Muze; Rosalynn Ord; Marnie Briceño; Brian M Greenwood; Chris Drakeley; Christopher J M Whitty
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.